Xenon Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrea DiFabio
- Full Time Employees
- 316
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3650 Gilmore Way Burnaby BC Canada V5G 4W8
- IPO Date
- Nov 5, 2014
- CIK
- 0001582313
- Website
- xenon-pharma.com
- Similar Companies
- Business
- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company founded in 1996 and headquartered in Burnaby, British Columbia, Canada, with additional offices in Boston, Massachusetts, engages in the discovery, clinical development, and commercialization of novel therapeutics targeting neurological and psychiatric disorders through ion channel modulation. The company advances a differentiated pipeline led by its flagship product candidate azetukalner, a novel, potent, selective Kv7 potassium channel opener in multiple Phase 3 clinical trials for focal onset seizures (X-TOLE2, X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED); early-stage wholly-owned programs include XEN1120, a Kv7 potassium channel opener in Phase 1 for pain, and XEN1701, a Nav1.7 sodium channel inhibitor in Phase 1 for pain, alongside undisclosed preclinical Kv7 openers for epilepsy, pain, and psychiatry, Nav1.7 inhibitors for pain, and Nav1.1 sodium channel openers for Dravet syndrome. It also maintains a partnered program with Neurocrine Biosciences for NBI-921355 (formerly XEN901), a selective Nav1.2/1.6 sodium channel inhibitor in Phase 1 for epilepsy. Xenon serves patients with high unmet needs in epilepsy, depression, bipolar disorder, pain, and related neuropsychiatric conditions across North America and global clinical trial sites. Recent developments include completion of patient randomization in the Phase 3 X-TOLE2 trial for focal onset seizures with topline data expected in early 2026, ongoing recruitment in X-NOVA2/3 for major depressive disorder and X-CEED for bipolar depression, presentation of new long-term safety and efficacy data for azetukalner from the X-TOLE open-label extension at the American Epilepsy Society Annual Meeting in December 2025, and maintenance of a strong cash position of $555.3 million as of September 30, 2025, anticipated to fund operations into 2027 amid elevated R&D expenses for late-stage programs.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon to Present at Upcoming Investor Conferences
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough